These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38297337)

  • 21. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
    Capeding MR; Tadesse BT; Sil A; Alberto E; Kim DR; Park EL; Park JY; Yang JS; Eluru JR; Jo SK; Kim H; Yang SY; Ryu JH; Park H; Shin JH; Lee Y; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    NPJ Vaccines; 2022 Jan; 7(1):12. PubMed ID: 35087084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
    Theiss-Nyland K; Shakya M; Colin-Jones R; Voysey M; Smith N; Karkey A; Dongol S; Pant D; Farooq YG; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S67-S73. PubMed ID: 30845329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.
    Szu SC; Lin KF; Hunt S; Chu C; Thinh ND
    Vaccine; 2014 May; 32(22):2618-22. PubMed ID: 24657719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults.
    Loebermann M; Kollaritsch H; Ziegler T; Rendi-Wagner P; Chambonneau L; Dumas R; Lafrenz M
    Clin Ther; 2004 Jul; 26(7):1084-91. PubMed ID: 15336473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
    Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
    Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
    van Damme P; Kafeja F; Anemona A; Basile V; Hilbert AK; De Coster I; Rondini S; Micoli F; Qasim Khan RM; Marchetti E; Di Cioccio V; Saul A; Martin LB; Podda A
    PLoS One; 2011; 6(9):e25398. PubMed ID: 21980445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.
    Nampota-Nkomba N; Nyirenda OM; Khonde L; Mapemba V; Mbewe M; Ndaferankhande JM; Msuku H; Masesa C; Misiri T; Mwakiseghile F; Patel PD; Patel P; Johnson-Mayo I; Pasetti MF; Heyderman RS; Tracy JK; Datta S; Liang Y; Neuzil KM; Gordon MA; Laurens MB;
    Lancet Glob Health; 2022 Sep; 10(9):e1326-e1335. PubMed ID: 35961356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
    Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
    N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM
    Thuluva S; Paradkar V; Matur R; Turaga K; Gv SR
    Hum Vaccin Immunother; 2022 Nov; 18(5):2043103. PubMed ID: 35333702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono A; Nébié I; Konaté A; Berges GD; Diarra A; Ouedraogo M; Bougouma EC; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Oshinsky JJ; Pasetti MF; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jul; 108():465-472. PubMed ID: 34082090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
    Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants.
    Ok Baik Y; Lee Y; Lee C; Kyung Kim S; Park J; Sun M; Jung D; Young Jang J; Jun Yong T; Woo Park J; Jeong S; Lim S; Hyun Han S; Keun Choi S
    Vaccine; 2023 Mar; 41(10):1753-1759. PubMed ID: 36774331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.